Evidence map›Paper›PMID 39709431›Full record

ReviewJournal of hematology & oncology2024

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Yuhang Chen, Suoyi Dai, Chien-Shan Cheng, Lianyu Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. GPX8Oncogene · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Targeting Tumor-Associated Macrophages and Cancer-Associated Fibroblasts to Overcome Therapeutic Resistance in Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  16. Review
  17. Article
  18. The Role of CD4Cells · 2026
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuhang Chen *Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Suoyi Dai *Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Chien-Shan ChengDepartment of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. natcheng@connect.hku.hk.
Lianyu ChenDepartment of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. lianyu-chen@alu.fudan.edu.cn.

Funding

National Natural Science Foundation of China 82374246, 82174169
6 · The paper itself

Abstract

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its primary mechanism of action involves inhibiting signal pathways such as vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), thereby reducing tumor cell proliferation and angiogenesis and affecting the tumor's immune microenvironment. In the treatment of liver cancer, although lenvatinib monotherapy has shown good clinical effect, the problem of drug resistance is becoming more and more serious. This resistance may be caused by a variety of factors, including genetic mutations, signaling pathway remodeling, and changes in the tumor microenvironment. In order to overcome drug resistance, the combination of lenvatinib and other therapeutic strategies has gradually become a research hotspot, and it is worth noting that the combination of lenvatinib and immune checkpoint inhibitors (ICIs) has shown a good application prospect. This combination not only enhances the anti-tumor immune response but also helps improve therapeutic efficacy. However, combination therapy also faces challenges regarding safety and tolerability. Therefore, studying the mechanisms of resistance and identifying relevant biomarkers is particularly important, as it aids in early diagnosis and personalized treatment. This article reviews the mechanisms of lenvatinib in treating liver cancer, the mechanisms and efficacy of its combination with immune checkpoint inhibitors, the causes of resistance, the exploration of biomarkers, and other novel combination therapy strategies for lenvatinib. We hope to provide insights into the use and research of lenvatinib in clinical and scientific settings, offering new strategies for the treatment of liver cancer.

Indexed as

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsPhenylurea CompoundsQuinolinesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmHumansProtein Kinase InhibitorsTumor MicroenvironmentAntineoplastic AgentsImmune Checkpoint InhibitorslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesHepatocellular carcinomaImmune-checkpoint inhibitors (ICIs)LenvatinibTyrosine kinase inhibitor (TKI)

Identifiers

PMID39709431
PMCPMC11663365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.